Axiom Space and Exobiosphere Plan Microgravity Drug-Discovery Research
Published in Drugs development & discovery, Tools.
October 7, 2026
Axiom Space and Exobiosphere announced a memorandum of understanding on October 7 to collaborate on biomedical research in low-Earth orbit. The proposed work would use Axiom Space private astronaut missions and the future Axiom Station to support disease modeling and drug discovery in microgravity.
Exobiosphere’s automated Orbital High-Throughput Screening platform is intended to run thousands of experiments alongside matched controls on Earth. The companies envision pharmaceutical and biotechnology researchers incorporating these orbital experiments into their existing research programs.
The agreement also outlines cooperation on crew and cargo access, identification of research infrastructure opportunities, and exploration of in-space manufacturing.
This is a research collaboration framework. The announcement does not report completed screening results, a demonstrated improvement in drug discovery, or patient outcomes. Whether orbital experiments generate useful therapeutic leads remains to be established through subsequent studies.